Global Tissue Diagnostic Market Research And Analysis, 2015-2020
Market Insight:
Global Tissue Diagnostic Market is expected to exceed $5 billion in 2020 with a CAGR 7.2% during 2015-2020. The rising incidence and prevalence rate of cancer gave rise to tissue diagnostic market. Cancer is a fetal disease and it is prevalent across the globe with huge economic burden in emerging and low-middle income group countries. It has considerable presence in developed and developing economies such as US, UK, Spain, China, India and Korea. Tissue diagnosis includes Hematoxylin & Eosin (H&E) Stain, Immunohistochemistry (IHC) Test, Fluorescent In Situ Hybridization (FISH) Test, Silver In Situ Hybridization (SISH) Test, Pathology and other stain tests. These diagnostic services are widely available and due to technological advancement, innovation and efficient results these diagnostic devices are in huge demand.
Global tissue diagnostic market is expected to grow significantly due to rise in adoption of personalized healthcare, in-vitro diagnostic, incidence and prevalence rate of cancer. The results of research & development and critical FDA approvals on diagnostic devices enable the tissue diagnostic market to grow fast. Funding from government and private players are also key factors to drive the global tissue diagnostic market. However, high cost of tissue diagnostic and less awareness among emerging and low-middle income group countries are concern for the growth tissue diagnostic market.
Regional Insights:
North America generates highest revenues across the globe due to huge number of Cancer patients and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for tissue diagnostic market. Improved healthcare spending, infrastructure and favorable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.
The report also covers various factors that influence the market such as the government regulations, drug and device laws and regulations, regulations on clinical trials, government policies and so on are covered at length. The report also covers parametric analysis, historical analysis and tissue diagnosis which includes various test such as Hematoxylin and silver in situ hybridization test. Global tissue diagnostic market is segmented on the basis of technology, diagnosis, product, end user and geography. Global tissue diagnostic market by diagnosis and end user are expected to contribute significantly due to huge demand created by cancer patients.
COMPETITIVE INSIGHTS:
The key players of global tissue diagnostic market includes Abbott Laboratories, Roche Holdings AG, Biogenex Laboratories, Bio SB, Agilent Technologies Cell Signaling Technology, Danaher Corporation, Sigma-Aldrich, Thermo Fisher Scientific, Qiagen, Becton Dickinson & company, Alere, Diagenic, Stryker, Biomeriux, Promethius Laboratories, Life Technologies, GE healthcare, Philips, Siemens, Johnson & Johnson, Quest Diagnostic, Axxin, Caris Life Sciences, Singulux, Teco Diagnostic, Ribomed, Signal Genetics and so on.
MARKET SEGMENTATION:
Global Tissue Diagnostic Market is segmented on the basis of technology, product, diagnosis, end user and region. Global tissue diagnostic market by technology and end user has significant contribution in generating huge revenues across the geographies. The global tissue diagnostic market by technology includes Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow Management, Magnetoencephalograph and so on. The rising Cancer patients created huge demand for diagnostic technology and devices.
Global Tissue Diagnostic Market is expected to exceed $5 billion in 2020 with a CAGR 7.2% during 2015-2020. The rising incidence and prevalence rate of cancer gave rise to tissue diagnostic market. Cancer is a fetal disease and it is prevalent across the globe with huge economic burden in emerging and low-middle income group countries. It has considerable presence in developed and developing economies such as US, UK, Spain, China, India and Korea. Tissue diagnosis includes Hematoxylin & Eosin (H&E) Stain, Immunohistochemistry (IHC) Test, Fluorescent In Situ Hybridization (FISH) Test, Silver In Situ Hybridization (SISH) Test, Pathology and other stain tests. These diagnostic services are widely available and due to technological advancement, innovation and efficient results these diagnostic devices are in huge demand.
Global tissue diagnostic market is expected to grow significantly due to rise in adoption of personalized healthcare, in-vitro diagnostic, incidence and prevalence rate of cancer. The results of research & development and critical FDA approvals on diagnostic devices enable the tissue diagnostic market to grow fast. Funding from government and private players are also key factors to drive the global tissue diagnostic market. However, high cost of tissue diagnostic and less awareness among emerging and low-middle income group countries are concern for the growth tissue diagnostic market.
Regional Insights:
North America generates highest revenues across the globe due to huge number of Cancer patients and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for tissue diagnostic market. Improved healthcare spending, infrastructure and favorable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.
The report also covers various factors that influence the market such as the government regulations, drug and device laws and regulations, regulations on clinical trials, government policies and so on are covered at length. The report also covers parametric analysis, historical analysis and tissue diagnosis which includes various test such as Hematoxylin and silver in situ hybridization test. Global tissue diagnostic market is segmented on the basis of technology, diagnosis, product, end user and geography. Global tissue diagnostic market by diagnosis and end user are expected to contribute significantly due to huge demand created by cancer patients.
COMPETITIVE INSIGHTS:
The key players of global tissue diagnostic market includes Abbott Laboratories, Roche Holdings AG, Biogenex Laboratories, Bio SB, Agilent Technologies Cell Signaling Technology, Danaher Corporation, Sigma-Aldrich, Thermo Fisher Scientific, Qiagen, Becton Dickinson & company, Alere, Diagenic, Stryker, Biomeriux, Promethius Laboratories, Life Technologies, GE healthcare, Philips, Siemens, Johnson & Johnson, Quest Diagnostic, Axxin, Caris Life Sciences, Singulux, Teco Diagnostic, Ribomed, Signal Genetics and so on.
MARKET SEGMENTATION:
Global Tissue Diagnostic Market is segmented on the basis of technology, product, diagnosis, end user and region. Global tissue diagnostic market by technology and end user has significant contribution in generating huge revenues across the geographies. The global tissue diagnostic market by technology includes Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow Management, Magnetoencephalograph and so on. The rising Cancer patients created huge demand for diagnostic technology and devices.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. PARAMETRIC ANALYSIS
2.4.1. RISING INCIDENCE AND PREVALENCE RATE OF CANCER
2.4.2. RISING PREVALENCE & INCIDENCE RATE OF NEURO-DEGENERATIVE DISEASES
2.4.3. RISING DIAGNOSTIC CENTRES ACROSS GEOGRAPHIES
2.4.4. RISING LABORATORIES ACROSS GEOGRAPHIES
2.4.5. HOSPITAL AND RESEARCH CENTRE ON RISE
2.5. CURRENT MARKET TRENDS
2.6. TISSUE DIAGNOSIS
2.6.1. HEMATOXYLIN & EOSIN (H&E) STAIN
2.6.2. IMMUNOHISTOCHEMISTRY (IHC) TEST
2.6.3. FLUORESCENT IN SITU HYBRIDIZATION (FISH) TEST
2.6.4. SILVER IN SITU HYBRIDIZATION (SISH) TEST
2.7. ANALYST INSIGHT
2.7.1. KEY FINDINGS
2.7.2. RECOMMENDATION
2.7.3. CONCLUSION
2.8. REGULATION
2.8.1. REGULATIONS ON CLINICAL TRIALS
2.8.1.1. FDA REGULATIONS
2.8.1.1.1. UNITED STATES
2.8.1.1.2. EUROPEAN UNION
2.8.1.1.3. CHINA
2.8.1.1.4. INDIA
2.8.1.1.5. REST OF THE WORLD
2.8.1.2. DRUG AND DEVICE REGULATIONS
2.8.1.2.1. UNITED STATES
2.8.1.2.2. EUROPEAN UNION
2.8.1.2.3. CHINA
2.8.1.2.4. INDIA
2.8.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN PERSONALIZED HEALTHCARE
3.1.2. RISING IN-VITRO DIAGNOSTICS ENABLES TISSUE DIAGNOSTIC MARKET TO GROW SIGNIFICANTLY
3.1.3. RISE IN CANCER INCIDENCE & PREVALENCE
3.1.4. FDA APPROVALS ARE ON RISE AND MAY ATTRACT OTHER BIG PLAYERS TO ENTER INTO THE TISSUE DIAGNOSTIC MARKET
3.1.5. RISE IN ADOPTION OF CANCER DIAGNOSTICS AND TREATMENT
3.1.6. TECHNOLOGICAL ADVANCEMENT IN TISSUE DIAGNOSTIC
3.1.7. DEVELOPMENT IN PROTEOMICS AND GENOMICS
3.1.8. INNOVATION IN DIAGNOSTIC AND TREATMENT
3.1.9. FAVOURABLE GOVERNMENT POLICIES AND REGULATIONS
3.1.10. RESEARCH & DEVELOPMENT TO DRIVE THE TISSUE DIAGNOSTIC MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF DIAGNOSIS & TREATMENT
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3. OPPORTUNITY
3.3.1. COST SAVING FOR LABORATORIES DUE TO EFFICIENT TISSUE DIAGNOSTIC DEVICES
3.3.2. ADOPTION OF LAB AUTOMATION TECHNOLOGY IN TISSUE DIAGNOSTIC
3.3.3. UNTAPPED APAC REGION IS FULL OF OPPORTUNITY FOR GLOBAL TISSUE DIAGNOSTIC MARKET
3.3.4. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
3.3.5. COLLABORATION AND PARTNERSHIP IN TISSUE DIAGNOSTIC MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY TECHNOLOGY 2014-2020, ($ MILLIONS)
5.1.1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2021, ($ MILLIONS)
5.1.2. GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.4. GLOBAL MAGNETOENCEPHALOGRAPH MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.5. GLOBAL SPECIAL STAINING MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL GASTRIC CANCER MARKET, 2014-2021, ($ MILLIONS)
5.2.3. GLOBAL LYMPHOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.4. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.5. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.6. GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
5.3.1. GLOBAL INSTRUMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.1. GLOBAL SLIDE STAINING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.2. GLOBAL SCANNERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.3. GLOBAL TISSUE PROCESSING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.4. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2. GLOBAL CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.1. GLOBAL ANTIBODY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.2. GLOBAL KITS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.3. GLOBAL REAGENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.4. GLOBAL PROBES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.5. GLOBAL OTHER CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
5.4.1. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.2. GLOBAL PHARMACEUTICALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.3. GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.4. GLOBAL LABORATORIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.5. GLOBAL OTHER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. ROCHE HOLDINGS AG
8.1.1. INTRODUCTION
8.1.2. ROCHE HOLDINGS AG PRODUCT PORTFOLIO
8.1.3. ROCHE HOLDINGS AG RECENT ACTIVITIES
8.1.4. ROCHE HOLDINGS AG SWOT
8.2. BIOGENEX LABORATORIES
8.2.1. INTRODUCTION
8.2.2. BIOGENEX LABORATORIES PRODUCT PORTFOLIO
8.2.3. BIOGENEX LABORATORIES RECENT ACTIVITIES
8.2.4. BIOGENEX LABORATORIES SWOT
8.3. BIO SB.
8.3.1. INTRODUCTION
8.3.2. BIO SG PRODUCT PORTFOLIO
8.3.3. BIO SG RECENT ACTIVITIES
8.3.4. BIO SG SWOT
8.4. CELL SIGNALLING TECHNOLOGY, INC.
8.4.1. INTRODUCTION
8.4.2. CELL SIGNALLING TECHNOLOGY PRODUCT PORTFOLIO
8.4.3. CELL SIGNALLING TECHNOLOGY RECENT ACTIVITIES
8.4.4. CELL SIGNALLING TECHNOLOGY SWOT
8.5. QIAGEN
8.5.1. INTRODUCTION
8.5.2. QIAGEN PRODUCT PORTFOLIO
8.5.3. QIAGEN RECENT ACTIVITIES
8.5.4. QIAGEN SWOT
8.6. BECTON DICKINSON & COMPANY
8.6.1. INTRODUCTION
8.6.2. BECTON DICKINSON & COMPANY PRODUCT PORTFOLIO
8.6.3. BECTON DICKINSON & COMPANY RECENT ACTIVITIES
8.6.4. BECTON DICKINSON & COMPANY SWOT
8.7. ALERE
8.7.1. INTRODUCTION
8.7.2. ALERE PRODUCT PORTFOLIO
8.7.3. ALERE RECENT ACTIVITIES
8.7.4. ALERE SWOT
8.8. DIAGENIC
8.8.1. INTRODUCTION
8.8.2. DIAGENIC PRODUCT PORTFOLIO
8.8.3. DIAGENIC RECENT ACTIVITIES
8.8.4. DIAGENIC SWOT
8.9. STRYKER
8.9.1. INTRODUCTION
8.9.2. STRYKER PRODUCT PORTFOLIO
8.9.3. STRYKER RECENT ACTIVITIES
8.9.4. STRYKER SWOT
8.10. BIOMERIUX
8.10.1. INTRODUCTION
8.10.2. BIOMERIUX PRODUCT PORTFOLIO
8.10.3. BIOMERIUX RECENT ACTIVITIES
8.10.4. BIOMERIUX SWOT
8.11. PROMETHEUS LABORATORIES
8.11.1. INTRODUCTION
8.11.2. PROMETHEUS LABORATORIES PRODUCT PORTFOLIO
8.11.3. PROMETHEUS LABORATORIES RECENT ACTIVITIES
8.11.4. PROMETHEUS LABORATORIES SWOT
8.12. AGILENT TECHNOLOGIES
8.12.1. INTRODUCTION
8.12.2. AGILENT TECHNOLOGIES PRODUCT PORTFOLIO
8.12.3. AGILENT TECHNOLOGIES RECENT ACTIVITIES
8.12.4. AGILENT TECHNOLOGIES SWOT
8.13. DANAHER CORPORATION.
8.13.1. INTRODUCTION
8.13.2. DANAHER CORPORATION PRODUCT PORTFOLIO
8.13.3. DANAHER CORPORATION RECENT ACTIVITIES
8.13.4. DANAHER CORPORATION SWOT
8.14. LIFE TECHNOLOGIES
8.14.1. INTRODUCTION
8.14.2. LIFE TECHNOLOGIES PRODUCT PORTFOLIO
8.14.3. LIFE TECHNOLOGIES RECENT ACTIVITIES
8.14.4. LIFE TECHNOLOGIES SWOT
8.15. GE HEALTHCARE
8.15.1. INTRODUCTION
8.15.2. GE HEALTHCARE PRODUCT PORTFOLIO
8.15.3. GE HEALTHCARE RECENT ACTIVITIES
8.15.4. GE HEALTHCARE SWOT
8.16. PHILIPS
8.16.1. INTRODUCTION
8.16.2. PHILIPS PRODUCT PORTFOLIO
8.16.3. PHILIPS RECENT ACTIVITIES
8.16.4. PHILIPS SWOT
8.17. SIEMENS
8.17.1. INTRODUCTION
8.17.2. SIEMENS PRODUCT PORTFOLIO
8.17.3. SIEMENS RECENT ACTIVITIES
8.17.4. SIEMENS SWOT
8.18. JOHNSON & JOHNSON
8.18.1. INTRODUCTION
8.18.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
8.18.3. JOHNSON & JOHNSON RECENT ACTIVITIES
8.18.4. JOHNSON & JOHNSON SWOT
8.19. QUEST DIAGNOSTIC
8.19.1. INTRODUCTION
8.19.2. QUEST DIAGNOSTIC PRODUCT PORTFOLIO
8.19.3. QUEST DIAGNOSTIC RECENT ACTIVITIES
8.19.4. QUEST DIAGNOSTIC SWOT
8.20. AXXIN
8.20.1. INTRODUCTION
8.20.2. AXXIN PRODUCT PORTFOLIO
8.20.3. AXXIN RECENT ACTIVITIES
8.20.4. AXXIN SWOT
8.21. CARIS LIFE SCIENCES
8.21.1. INTRODUCTION
8.21.2. CARIS LIFE SCIENCES PRODUCT PORTFOLIO
8.21.3. CARIS LIFE SCIENCES RECENT ACTIVITIES
8.21.4. CARIS LIFE SCIENCES SWOT
8.22. SINGULEX
8.22.1. INTRODUCTION
8.22.2. SINGULEX PRODUCT PORTFOLIO
8.22.3. SINGULEX RECENT ACTIVITIES
8.22.4. SINGULEX SWOT
8.23. TECO DIAGNOSTICS
8.23.1. INTRODUCTION
8.23.2. TECO DIAGNOSTICS PRODUCT PORTFOLIO
8.23.3. TECO DIAGNOSTICS RECENT ACTIVITIES
8.23.4. TECO DIAGNOSTICS SWOT
8.24. RIBOMED
8.24.1. INTRODUCTION
8.24.2. RIBOMED PRODUCT PORTFOLIO
8.24.3. RIBOMED RECENT ACTIVITIES
8.24.4. RIBOMED SWOT
8.25. SIGNAL GENETICS
8.25.1. INTRODUCTION
8.25.2. SIGNAL GENETICS PRODUCT PORTFOLIO
8.25.3. SIGNAL GENETICS RECENT ACTIVITIES
8.25.4. SIGNAL GENETICS SWOT
8.26. TRINITY BIOTECH
8.26.1. INTRODUCTION
8.26.2. TRINITY BIOTECH PRODUCT PORTFOLIO
8.26.3. TRINITY BIOTECH RECENT ACTIVITIES
8.26.4. TRINITY BIOTECH SWOT
8.27. NOVARTIS DIAGNOSTICS
8.27.1. INTRODUCTION
8.27.2. NOVARTIS DIAGNOSTICS PRODUCT PORTFOLIO
8.27.3. NOVARTIS DIAGNOSTICS RECENT ACTIVITIES
8.27.4. NOVARTIS DIAGNOSTICS SWOT
8.28. NOVODIAX
8.28.1. INTRODUCTION
8.28.2. NOVODIAX PRODUCT PORTFOLIO
8.28.3. NOVODIAX RECENT ACTIVITIES
8.28.4. NOVODIAX SWOT
8.29. BIOCEPT
8.29.1. INTRODUCTION
8.29.2. BIOCEPT PRODUCT PORTFOLIO
8.29.3. BIOCEPT RECENT ACTIVITIES
8.29.4. BIOCEPT SWOT
8.30. EUROGENTEC
8.30.1. INTRODUCTION
8.30.2. EUROGENTEC PRODUCT PORTFOLIO
8.30.3. EUROGENTEC RECENT ACTIVITIES
8.30.4. EUROGENTEC SWOT
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. PARAMETRIC ANALYSIS
2.4.1. RISING INCIDENCE AND PREVALENCE RATE OF CANCER
2.4.2. RISING PREVALENCE & INCIDENCE RATE OF NEURO-DEGENERATIVE DISEASES
2.4.3. RISING DIAGNOSTIC CENTRES ACROSS GEOGRAPHIES
2.4.4. RISING LABORATORIES ACROSS GEOGRAPHIES
2.4.5. HOSPITAL AND RESEARCH CENTRE ON RISE
2.5. CURRENT MARKET TRENDS
2.6. TISSUE DIAGNOSIS
2.6.1. HEMATOXYLIN & EOSIN (H&E) STAIN
2.6.2. IMMUNOHISTOCHEMISTRY (IHC) TEST
2.6.3. FLUORESCENT IN SITU HYBRIDIZATION (FISH) TEST
2.6.4. SILVER IN SITU HYBRIDIZATION (SISH) TEST
2.7. ANALYST INSIGHT
2.7.1. KEY FINDINGS
2.7.2. RECOMMENDATION
2.7.3. CONCLUSION
2.8. REGULATION
2.8.1. REGULATIONS ON CLINICAL TRIALS
2.8.1.1. FDA REGULATIONS
2.8.1.1.1. UNITED STATES
2.8.1.1.2. EUROPEAN UNION
2.8.1.1.3. CHINA
2.8.1.1.4. INDIA
2.8.1.1.5. REST OF THE WORLD
2.8.1.2. DRUG AND DEVICE REGULATIONS
2.8.1.2.1. UNITED STATES
2.8.1.2.2. EUROPEAN UNION
2.8.1.2.3. CHINA
2.8.1.2.4. INDIA
2.8.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISE IN PERSONALIZED HEALTHCARE
3.1.2. RISING IN-VITRO DIAGNOSTICS ENABLES TISSUE DIAGNOSTIC MARKET TO GROW SIGNIFICANTLY
3.1.3. RISE IN CANCER INCIDENCE & PREVALENCE
3.1.4. FDA APPROVALS ARE ON RISE AND MAY ATTRACT OTHER BIG PLAYERS TO ENTER INTO THE TISSUE DIAGNOSTIC MARKET
3.1.5. RISE IN ADOPTION OF CANCER DIAGNOSTICS AND TREATMENT
3.1.6. TECHNOLOGICAL ADVANCEMENT IN TISSUE DIAGNOSTIC
3.1.7. DEVELOPMENT IN PROTEOMICS AND GENOMICS
3.1.8. INNOVATION IN DIAGNOSTIC AND TREATMENT
3.1.9. FAVOURABLE GOVERNMENT POLICIES AND REGULATIONS
3.1.10. RESEARCH & DEVELOPMENT TO DRIVE THE TISSUE DIAGNOSTIC MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF DIAGNOSIS & TREATMENT
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3. OPPORTUNITY
3.3.1. COST SAVING FOR LABORATORIES DUE TO EFFICIENT TISSUE DIAGNOSTIC DEVICES
3.3.2. ADOPTION OF LAB AUTOMATION TECHNOLOGY IN TISSUE DIAGNOSTIC
3.3.3. UNTAPPED APAC REGION IS FULL OF OPPORTUNITY FOR GLOBAL TISSUE DIAGNOSTIC MARKET
3.3.4. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
3.3.5. COLLABORATION AND PARTNERSHIP IN TISSUE DIAGNOSTIC MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY TECHNOLOGY 2014-2020, ($ MILLIONS)
5.1.1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2021, ($ MILLIONS)
5.1.2. GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.4. GLOBAL MAGNETOENCEPHALOGRAPH MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.5. GLOBAL SPECIAL STAINING MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL GASTRIC CANCER MARKET, 2014-2021, ($ MILLIONS)
5.2.3. GLOBAL LYMPHOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.4. GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.5. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.6. GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
5.3.1. GLOBAL INSTRUMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.1. GLOBAL SLIDE STAINING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.2. GLOBAL SCANNERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.3. GLOBAL TISSUE PROCESSING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.1.4. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2. GLOBAL CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.1. GLOBAL ANTIBODY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.2. GLOBAL KITS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.3. GLOBAL REAGENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.4. GLOBAL PROBES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2.5. GLOBAL OTHER CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4. GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
5.4.1. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.2. GLOBAL PHARMACEUTICALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.3. GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.4. GLOBAL LABORATORIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.4.5. GLOBAL OTHER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. ROCHE HOLDINGS AG
8.1.1. INTRODUCTION
8.1.2. ROCHE HOLDINGS AG PRODUCT PORTFOLIO
8.1.3. ROCHE HOLDINGS AG RECENT ACTIVITIES
8.1.4. ROCHE HOLDINGS AG SWOT
8.2. BIOGENEX LABORATORIES
8.2.1. INTRODUCTION
8.2.2. BIOGENEX LABORATORIES PRODUCT PORTFOLIO
8.2.3. BIOGENEX LABORATORIES RECENT ACTIVITIES
8.2.4. BIOGENEX LABORATORIES SWOT
8.3. BIO SB.
8.3.1. INTRODUCTION
8.3.2. BIO SG PRODUCT PORTFOLIO
8.3.3. BIO SG RECENT ACTIVITIES
8.3.4. BIO SG SWOT
8.4. CELL SIGNALLING TECHNOLOGY, INC.
8.4.1. INTRODUCTION
8.4.2. CELL SIGNALLING TECHNOLOGY PRODUCT PORTFOLIO
8.4.3. CELL SIGNALLING TECHNOLOGY RECENT ACTIVITIES
8.4.4. CELL SIGNALLING TECHNOLOGY SWOT
8.5. QIAGEN
8.5.1. INTRODUCTION
8.5.2. QIAGEN PRODUCT PORTFOLIO
8.5.3. QIAGEN RECENT ACTIVITIES
8.5.4. QIAGEN SWOT
8.6. BECTON DICKINSON & COMPANY
8.6.1. INTRODUCTION
8.6.2. BECTON DICKINSON & COMPANY PRODUCT PORTFOLIO
8.6.3. BECTON DICKINSON & COMPANY RECENT ACTIVITIES
8.6.4. BECTON DICKINSON & COMPANY SWOT
8.7. ALERE
8.7.1. INTRODUCTION
8.7.2. ALERE PRODUCT PORTFOLIO
8.7.3. ALERE RECENT ACTIVITIES
8.7.4. ALERE SWOT
8.8. DIAGENIC
8.8.1. INTRODUCTION
8.8.2. DIAGENIC PRODUCT PORTFOLIO
8.8.3. DIAGENIC RECENT ACTIVITIES
8.8.4. DIAGENIC SWOT
8.9. STRYKER
8.9.1. INTRODUCTION
8.9.2. STRYKER PRODUCT PORTFOLIO
8.9.3. STRYKER RECENT ACTIVITIES
8.9.4. STRYKER SWOT
8.10. BIOMERIUX
8.10.1. INTRODUCTION
8.10.2. BIOMERIUX PRODUCT PORTFOLIO
8.10.3. BIOMERIUX RECENT ACTIVITIES
8.10.4. BIOMERIUX SWOT
8.11. PROMETHEUS LABORATORIES
8.11.1. INTRODUCTION
8.11.2. PROMETHEUS LABORATORIES PRODUCT PORTFOLIO
8.11.3. PROMETHEUS LABORATORIES RECENT ACTIVITIES
8.11.4. PROMETHEUS LABORATORIES SWOT
8.12. AGILENT TECHNOLOGIES
8.12.1. INTRODUCTION
8.12.2. AGILENT TECHNOLOGIES PRODUCT PORTFOLIO
8.12.3. AGILENT TECHNOLOGIES RECENT ACTIVITIES
8.12.4. AGILENT TECHNOLOGIES SWOT
8.13. DANAHER CORPORATION.
8.13.1. INTRODUCTION
8.13.2. DANAHER CORPORATION PRODUCT PORTFOLIO
8.13.3. DANAHER CORPORATION RECENT ACTIVITIES
8.13.4. DANAHER CORPORATION SWOT
8.14. LIFE TECHNOLOGIES
8.14.1. INTRODUCTION
8.14.2. LIFE TECHNOLOGIES PRODUCT PORTFOLIO
8.14.3. LIFE TECHNOLOGIES RECENT ACTIVITIES
8.14.4. LIFE TECHNOLOGIES SWOT
8.15. GE HEALTHCARE
8.15.1. INTRODUCTION
8.15.2. GE HEALTHCARE PRODUCT PORTFOLIO
8.15.3. GE HEALTHCARE RECENT ACTIVITIES
8.15.4. GE HEALTHCARE SWOT
8.16. PHILIPS
8.16.1. INTRODUCTION
8.16.2. PHILIPS PRODUCT PORTFOLIO
8.16.3. PHILIPS RECENT ACTIVITIES
8.16.4. PHILIPS SWOT
8.17. SIEMENS
8.17.1. INTRODUCTION
8.17.2. SIEMENS PRODUCT PORTFOLIO
8.17.3. SIEMENS RECENT ACTIVITIES
8.17.4. SIEMENS SWOT
8.18. JOHNSON & JOHNSON
8.18.1. INTRODUCTION
8.18.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
8.18.3. JOHNSON & JOHNSON RECENT ACTIVITIES
8.18.4. JOHNSON & JOHNSON SWOT
8.19. QUEST DIAGNOSTIC
8.19.1. INTRODUCTION
8.19.2. QUEST DIAGNOSTIC PRODUCT PORTFOLIO
8.19.3. QUEST DIAGNOSTIC RECENT ACTIVITIES
8.19.4. QUEST DIAGNOSTIC SWOT
8.20. AXXIN
8.20.1. INTRODUCTION
8.20.2. AXXIN PRODUCT PORTFOLIO
8.20.3. AXXIN RECENT ACTIVITIES
8.20.4. AXXIN SWOT
8.21. CARIS LIFE SCIENCES
8.21.1. INTRODUCTION
8.21.2. CARIS LIFE SCIENCES PRODUCT PORTFOLIO
8.21.3. CARIS LIFE SCIENCES RECENT ACTIVITIES
8.21.4. CARIS LIFE SCIENCES SWOT
8.22. SINGULEX
8.22.1. INTRODUCTION
8.22.2. SINGULEX PRODUCT PORTFOLIO
8.22.3. SINGULEX RECENT ACTIVITIES
8.22.4. SINGULEX SWOT
8.23. TECO DIAGNOSTICS
8.23.1. INTRODUCTION
8.23.2. TECO DIAGNOSTICS PRODUCT PORTFOLIO
8.23.3. TECO DIAGNOSTICS RECENT ACTIVITIES
8.23.4. TECO DIAGNOSTICS SWOT
8.24. RIBOMED
8.24.1. INTRODUCTION
8.24.2. RIBOMED PRODUCT PORTFOLIO
8.24.3. RIBOMED RECENT ACTIVITIES
8.24.4. RIBOMED SWOT
8.25. SIGNAL GENETICS
8.25.1. INTRODUCTION
8.25.2. SIGNAL GENETICS PRODUCT PORTFOLIO
8.25.3. SIGNAL GENETICS RECENT ACTIVITIES
8.25.4. SIGNAL GENETICS SWOT
8.26. TRINITY BIOTECH
8.26.1. INTRODUCTION
8.26.2. TRINITY BIOTECH PRODUCT PORTFOLIO
8.26.3. TRINITY BIOTECH RECENT ACTIVITIES
8.26.4. TRINITY BIOTECH SWOT
8.27. NOVARTIS DIAGNOSTICS
8.27.1. INTRODUCTION
8.27.2. NOVARTIS DIAGNOSTICS PRODUCT PORTFOLIO
8.27.3. NOVARTIS DIAGNOSTICS RECENT ACTIVITIES
8.27.4. NOVARTIS DIAGNOSTICS SWOT
8.28. NOVODIAX
8.28.1. INTRODUCTION
8.28.2. NOVODIAX PRODUCT PORTFOLIO
8.28.3. NOVODIAX RECENT ACTIVITIES
8.28.4. NOVODIAX SWOT
8.29. BIOCEPT
8.29.1. INTRODUCTION
8.29.2. BIOCEPT PRODUCT PORTFOLIO
8.29.3. BIOCEPT RECENT ACTIVITIES
8.29.4. BIOCEPT SWOT
8.30. EUROGENTEC
8.30.1. INTRODUCTION
8.30.2. EUROGENTEC PRODUCT PORTFOLIO
8.30.3. EUROGENTEC RECENT ACTIVITIES
8.30.4. EUROGENTEC SWOT
LIST OF TABLES
TABLE # 1 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY TECHNOLOGY 2014-2020, ($ MILLIONS)
TABLE # 2 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2021, ($ MILLIONS)
TABLE # 3 GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 4 GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 5 GLOBAL MAGNETOENCEPHALOGRAPH MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 6 GLOBAL SPECIAL STAINING MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 7 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY DIOGNOSIS 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL GASTRIC CANCER MARKET, 2014-2021, ($ MILLIONS)
TABLE # 10 GLOBAL LYMPHOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL INSTRUMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL SLIDE STAINING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL SCANNERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 18 GLOBAL TISSUE PROCESSING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 21 GLOBAL ANTIBODY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 22 GLOBAL KITS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 23 GLOBAL REAGENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 24 GLOBAL PROBES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 25 GLOBAL OTHER CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 26 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
TABLE # 27 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 28 GLOBAL PHARMACEUTICALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 29 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 30 GLOBAL LABORATORIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 31 GLOBAL OTHER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 1 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY TECHNOLOGY 2014-2020, ($ MILLIONS)
TABLE # 2 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2021, ($ MILLIONS)
TABLE # 3 GLOBAL IN SITU HYBRIDIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 4 GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 5 GLOBAL MAGNETOENCEPHALOGRAPH MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 6 GLOBAL SPECIAL STAINING MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 7 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY DIOGNOSIS 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL GASTRIC CANCER MARKET, 2014-2021, ($ MILLIONS)
TABLE # 10 GLOBAL LYMPHOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL PROSTATE CANCER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL INSTRUMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL SLIDE STAINING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL SCANNERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 18 GLOBAL TISSUE PROCESSING SYSTEMS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 21 GLOBAL ANTIBODY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 22 GLOBAL KITS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 23 GLOBAL REAGENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 24 GLOBAL PROBES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 25 GLOBAL OTHER CONSUMABLES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 26 GLOBAL TISSUE DIAGNOSTIC MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
TABLE # 27 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 28 GLOBAL PHARMACEUTICALS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 29 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 30 GLOBAL LABORATORIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 31 GLOBAL OTHER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. ROCHE HOLDINGS AG
2. BIOGENEX LABORATORIES
3. BIO SB.
4. CELL SIGNALLING TECHNOLOGY, INC.
5. QIAGEN
6. BECTON DICKINSON & COMPANY
7. ALERE
8. DIAGENIC
9. STRYKER
10. BIOMERIUX
11. PROMETHEUS LABORATORIES
12. AGILENT TECHNOLOGIES
13. DANAHER CORPORATION.
14. LIFE TECHNOLOGIES
15. GE HEALTHCARE
16. PHILIPS
17. SIEMENS
18. JOHNSON & JOHNSON
19. QUEST DIAGNOSTIC
20. AXXIN
21. CARIS LIFE SCIENCES
22. SINGULEX
23. TECO DIAGNOSTICS
24. RIBOMED
25. SIGNAL GENETICS
26. TRINITY BIOTECH
27. NOVARTIS DIAGNOSTICS
28. NOVODIAX
29. BIOCEPT
30. EUROGENTEC
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. ROCHE HOLDINGS AG
2. BIOGENEX LABORATORIES
3. BIO SB.
4. CELL SIGNALLING TECHNOLOGY, INC.
5. QIAGEN
6. BECTON DICKINSON & COMPANY
7. ALERE
8. DIAGENIC
9. STRYKER
10. BIOMERIUX
11. PROMETHEUS LABORATORIES
12. AGILENT TECHNOLOGIES
13. DANAHER CORPORATION.
14. LIFE TECHNOLOGIES
15. GE HEALTHCARE
16. PHILIPS
17. SIEMENS
18. JOHNSON & JOHNSON
19. QUEST DIAGNOSTIC
20. AXXIN
21. CARIS LIFE SCIENCES
22. SINGULEX
23. TECO DIAGNOSTICS
24. RIBOMED
25. SIGNAL GENETICS
26. TRINITY BIOTECH
27. NOVARTIS DIAGNOSTICS
28. NOVODIAX
29. BIOCEPT
30. EUROGENTEC
